[{"orgOrder":0,"company":"Kyoto University","sponsor":"Tokushima University | Kitasato University | Tottori University | Nara Medical University | Toho University | Hiroshima University | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Kyoto University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kyoto University \/ Tokushima University | Kitasato University | Tottori University | Nara Medical University | Toho University | Hiroshima University | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Kyoto University \/ Tokushima University | Kitasato University | Tottori University | Nara Medical University | Toho University | Hiroshima University | Pfizer Inc"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Children's Oncology Group \/ Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Dutch Childhood Oncology Group | Innovative Therapies for Children with Cancer Consortium | Pfizer Inc"},{"orgOrder":0,"company":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica","sponsor":"Pfizer Inc | F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica \/ Pfizer Inc | F. Hoffmann-La Roche","highestDevelopmentStatusID":"7","companyTruncated":"Fundaci\u00f3n Espa\u00f1ola para la Curaci\u00f3n de la Leucemia Mieloide Cr\u00f3nica \/ Pfizer Inc | F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bosutinib","moa":"Tyrosine-protein kinase SRC | Tyrosine-protein kinase ABL | Tyrosine-protein kinase Lyn | Tyrosine-protein kinase HCK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Bosutinib

Bosutinib
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Bosutinib

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

7 API Suppliers, 5 USDMF, 1 JDMF, 2 EU WC, 3 NDC API, 1 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

INTERMEDIATES

10 Intermediate Suppliers

10 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers, 4 Europe, 3 Listed Dossiers

DIGITAL CONTENT

18 News #PharmaBuzz

18 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 4 Regulatory FDF Prices

MARKET PLACE

3 APIs, 1 Intermediates

REF. STANDARDS & IMPURITIES

2 Others

2 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Pfizer Inc

U.S.A

Coatings Trends

Not Confirmed

02

Pfizer Inc

U.S.A

Coatings Trends

Not Confirmed

03

Fundación Española para la Curación de la Leucemia Mieloide Crónica

Country

Coatings Trends

Not Confirmed

04

Kyoto University

Country

Coatings Trends

Not Confirmed

05

Pfizer Inc

U.S.A

Coatings Trends

Not Confirmed

06

Children's Oncology Group

Country

Coatings Trends

Not Confirmed

07

Pfizer Inc

U.S.A

Coatings Trends

Not Confirmed

08

Pfizer Inc

U.S.A

Coatings Trends

Not Confirmed

09

Neurological Associates of West Los Angeles

Country

Coatings Trends

Not Confirmed

10

MD Anderson Cancer Center

Country

Coatings Trends

Not Confirmed

1
2